TABLE 2.

Antibiotic susceptibility interpretation of initial screening and validation of nonsusceptible B. pseudomallei isolates

Hospital and B. pseudomallei isolatea	Isolate	Clinical specimen	Antibioticb	Susceptibility interpretationc
				Initial screend		Validation at FTMe (BMD)
				Hospital	FTM (DD)
Hospital A
DR10212A	Primary	Pleural fluid	CAZ	R	R	R
			MEM	R	R	LS
DR10118A	Primary	Blood	AMC	I	S	S
DR10120A	Primary	Blood	AMC	I	S	S
Hospital C
DR30013A	Primary	Blood	CAZ	NA	R	R
Hospital D
DR40031A	Primary	Blood	CAZ	I	S	S
AMC	ND	S	I
Hospital E
DR50054E	Relapse	Sputum	AMC	ND	R	R
CAZ	S	R	R
MEM	S	S	LS
Hospital H
DR80176A	Primary	Sputum	MEM	R	S	S
DR80177A	Primary	Blood	MEM	R	S	S
DR80109A	Primary	Sputum	AMC	ND	I	I
DR80110A	Primary	Urine	AMC	ND	R	R
CAZ	S	S	I
Hospital I
DR90087A	Primary	Blood	CAZ	R	S	S
	MEM	R	S	S
	IPM	R	S	S
DR90049A	Primary	Blood	MEM	I	S	LS
DR90003A	Primary	Blood	IPM	R	S	S
DR90026A	Primary	Sputum	IPM	R	S	S
DR90036A	Primary	Blood	IPM	R	S	S
DR90045A	Primary	Sputum	IPM	R	S	S
DR90076A	Primary	Body fluid	IPM	R	S	S
DR90031E	Relapse	Pus	MEM	NA	I	LS

^aA, primary isolate; E, relapse isolate.

^bCAZ, ceftazidime; IPM, imipenem; MEM, meropenem; AMC, amoxicillin-clavulanic acid.

^cS, susceptible; I, intermediate; R, resistant; LS, less susceptible for meropenem; ND, not done; NA, not available; FTM, Faculty of Tropical Medicine, Mahidol University; DD, disk diffusion test.

^dAntibiotic susceptibility testing screening by hospitals and FTM as described in Fig. 1.

^eValidation by broth microdilution method (BMD) by FTM. Boldface indicates antibiotic-resistant or intermediate isolates.